| || |
Participate in the 2016 ADHD Challenge
Help raise ADHD awareness, show off your skills and help raise funds for ADHD Awareness and advocacy work across Canada, all at the same time!
The Centre for ADHD Awareness, Canada (CADDAC) urges every Canadian to participate in a challenge of their choice for the month of October in an effort to raise awareness of ADHD and help raise funds for ADHD awareness and advocacy work across Canada. Whether you are 6, 16 or 60+ we want you to decide on a personal challenge that you want to complete during the month of October, ADHD Awareness Month, and complete the challenge with the support of your sponsors.
Decide on a challenge.
Challenges could include:
* Something physical like, running, biking, swimming or Yoga (e.g. 20 minutes or aerobic exercise each day)
* Something more cerebral like meditation, or mindfulness (e.g. 10 minutes twice a day)
* Something educational like reading or, creative like painting or writing ( read a book each week, chapter every night)
The list is endless
Go to the CADDAC web site and register your challenge
Use our ADHD Awareness tools, fact sheets, info graphics, posters and recording to educate your friends and family about ADHD.
Step 4 (Optional)
Ask your family and friends to log onto the CADDAC web site, and donate a small amount (2, 5, 10, 20 dollars) to sponsor your challenge and help support ADHD awareness and advocacy efforts.
(CADDAC is not a charity, but rather a national not-for-profit, so charitable receipts will not be issued)
Join the online discussion about ADHD and your challenges on our Facebook page.
The most creative ideas will be posted on our Facebook page.
All participants who wish their names to be shared will be officially thanked on the CADDAC web site and all participants will receive a certificate of participation and appreciation.
To register your challenge click HERE
To sponsor a participant click HERE
Event page click HERE
Please Help Us Improve Our Organization
Can you spare a few minutes to take our survey Click HERE
Your Experiences When Switched to Generic ADHD Medications
Over the past few years CADDAC has been receiving anecdotal feedback from caregivers, adults with ADHD and physicians indicating a decrease in symptom control and an increase in side effects when switched to the generic version of Concerta. Since our nation-wide survey confirmed this anecdotal feedback CADDAC will be undertaking further advocacy work on this issue.
If you have experienced any of these issues and are willing to discuss this with us, please contact us at email@example.com outlining these issues and we will arrange a time for a quick telephone chat. Comparing Treatment Results in Adults Switched to Generic ADHD Medication
A recently published study, “A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA®) and generic novo-methylphenidate ER-C (NOVO-generic)” confirms concerns expressed to CADDAC over the past number of years by adults with ADHD, parents of children with ADHD and physicians treating patients with ADHD who have been switched to a generic medication. The objective of this study was to evaluate adult ADHD subject outcomes when they were switched from a stable dose of CONCERTA® to the same dose of generic Novo-methylphenidate ER-C®. Access detailed information HERE
BC Pharmacare Therapeutic Review Accepting Patient Submissions
Download printable document
BC PharmaCare is conducting a Therapeutic Review into the coverage of medications used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). BC Patients, caregivers and patient groups will have the opportunity to provide input as part of the process, between May 4th and June 1st, 2016 AT MIDNIGHT.
At this time in BC, Ritalin and Dexedrine – both short-acting medications – are the only fully covered treatment options. Concerta, a long-acting medication, is available but it is restricted to Special Authority requests.
That is why this Therapeutic Review is so important for patients, their caregivers and their loved ones.
How to Participate
Interested parties that meet the eligibility requirements, see below, can provide their input by visiting the Ministry of Health website http://www.gov.bc.ca/bcyourvoice and following the directions. You will be asked to give your perspective on how ADHD affects your life and the impact and benefits of the ADHD medication that you are currently taking, or have taken. Patient, caregiver and patient group eligibility requirements can be found HERE.
BC Physicians: Collective Letter to Minister Lake
Download Collective Letter
Medication treatment for ADHD is not a “one size fits all” scenario and individuals with ADHD have unique responses to different medications. It is essential that physicians can individualize treatment and prescribe as wide a group of medications as possible.
The Ministry of Health is currently conducting a review of ADHD treatment therapies. There are many clinical treatment factors to consider when making a balanced patient-centered decision about coverage. As experts and front line workers in the field BC physicians and mental health professionals believe that they should be a part of the conversation. They are requesting that a meeting be held with Minister Lake as soon as possible to discuss how experienced ADHD medical professionals will be an integral part in this review process.
If you are a medical professional in BC, we ask that you read the online collective letter to Minister Lake and, if you agree, sign the letter online by May 12th: https://www.surveymonkey.com/r/CADDRA-CADDAC-Letter-to-Minister
Up-date From Health Canada on Generic Medications
At the beginning of March CADDAC received a reply letter from Health Canada.View this letter Here.The letter reiterated what we have been told previously.Health Canada requires official reporting of a decrease in effectiveness of a generic when compared to the brand medication to scientifically validate this information. Health Canada states,"Consumers are encouraged to complete reports in conjunction with their health professional, so that additional information about their medical history can be included in order to make the reports more detailed and scientifically valid."
If you have had an issue with an ADHD or other mental health generic medication not being as effective or lasting as long as the brand name, we strongly encourage you to access our Adverse Reaction Form and Guide to assist you with submitting an online report. Also please encourage your physician to do so as well. If this reporting does not occur issues with generic medication substitution proving inferior will not be solved.
Ontario now requires that a trial on a generic or two generics, if two are available, with an adverse event (AE) report completed for each before a pharmacist will honor a "do not substitute" request from a physician for any medication supplied by the OPDP (Ontario Public Drug Program).The physician will need to supply the patient with copies of both AE reports with the prescription in order to get full coverage of the brand medication. You can access complete details Here.
Please note: This only applies if the government pays the full price for the brand name medication. If the patient has a patient benefit card, which can be accessed through Innovicares and Rxhelp the price of a brand product is covered and trials on generic medications are not required. For more information please access Innovicares Here (https://www.innovicares.ca/) for Concerta and Rxhelp Here (http://www.rxhelp.ca.en.default.aspx) for Strattera.
ADHD in Girls, CBC The Current Interview
This interview features Anna, a every insightful 17 year old who was diagnosed with ADHD at the age of 15, and Katherine Ellis, a Pulitzer Prize winning journalist who was diagnosed at 48 and has since then authored three books on ADHD, talking about their experiences. In addition, Dr. Doron Almagor, a child and adolescent psychiatrist and chair of CADDRA, shares his extensive medical knowledge on the subject of ADHD in girls. Access the interview Here.
2015 Survey on Experiences with Mental Health Medication/Generic Substitution
Over the past few years CADDAC has been receiving anecdotal evidence from caregivers, patients and treating physicians, indicating a decrease in the degree and length of symptom control and an increase in side effects when patients were switched from particular brand-name to generic medications. CADDAC joined in discussion with other organizations supporting those with mental health conditions to find a way to gain more insight into this potential issue. You can access the full statement outlining the organizations' understanding, agreement and goals for the survey Here
As a result a nation-wide survey was launched requesting feedback from individuals, caregivers and healthcare providers on existing knowledge and experience with brand name and generic medications.
The survey findings have been analyzed and summarized. Here are the findings pertinent to ADHD medications and two additional medications that might be used by some of you for co-occurring conditions.
On December the 14th CADDAC sent a letter to Barbara Sabourin, the Director General of the Therapeutics Product Directorate, Health Products and Food Branch of Health Canada summarizing the findings of a recent joint survey on mental health medications, and in particular issues that have been reported with generic medications. You can access the complete letter Here
Doctors Challenge BC Government to take Action on ADHD
December 08 2015 Media Release
BC Physician Advocacy Campaign
Since British Columbia is behind other provinces in providing a full range of medication treatment options for ADHD CADDAC, CADDRA and BC physicians have begun an advocacy campaign to let the BC government know that the current situation is seriously limiting treatment options for those accessing BC Pharmacare. Currently Ritalin and Dexadrine are the only medications for the treatment of individuals with ADHD fully covered by BC Pharmacare. Concerta is the only long-acting medication and it is restricted to Special Authority Request (only for the paediatric population after failing on Ritalin and Dexedrine).
Physicians with an interest in the treatment of ADHD are being asked to write letters expressing their concern. Please access BC Pharmacare Medication Coverage for more detailed information on the current situation, a copy of the latest letter sent to Minister Lake, and the BC Letter Writing Guide to assist physicians in writing and sending a letter to the BC government.
This site was last updated on September 06, 2016